Financials Zymeworks Inc.

Equities

ZYME

US98985Y1082

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-04-26 pm EDT 5-day change 1st Jan Change
8.26 USD +1.85% Intraday chart for Zymeworks Inc. -6.67% -20.50%

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 1,793 2,171 763 506.3 727.3 582.9 - -
Enterprise Value (EV) 1 1,494 1,929 561.2 506.3 569.8 287.2 227.9 582.9
P/E ratio -11.9 x -13.2 x -3.99 x 4.14 x -6.04 x -7.35 x -9.07 x -8.91 x
Yield - - - - - - - -
Capitalization / Revenue 60.7 x 55.7 x 28.6 x 1.23 x 9.57 x 6.56 x 5.2 x 4.13 x
EV / Revenue 50.6 x 49.5 x 21 x 1.23 x 7.5 x 3.23 x 2.03 x 4.13 x
EV / EBITDA -10.2 x -10.7 x -2.68 x 3.68 x -4.46 x -2.52 x -1.88 x -
EV / FCF -16.9 x -12.4 x -2.74 x - -4.72 x -3.93 x -2.35 x -
FCF Yield -5.9% -8.07% -36.5% - -21.2% -25.4% -42.6% -
Price to Book 7.32 x 5.81 x 3.07 x - - - - -
Nbr of stocks (in thousands) 39,438 45,946 46,554 64,414 70,002 70,568 - -
Reference price 2 45.46 47.26 16.39 7.860 10.39 8.260 8.260 8.260
Announcement Date 3/2/20 2/24/21 2/24/22 3/7/23 3/6/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 29.54 38.95 26.68 412.5 76.01 88.9 112.2 141
EBITDA 1 -145.9 -180 -209.1 137.8 -127.9 -113.9 -121.2 -
EBIT 1 -150.5 -187.5 -215.6 130.5 -138.1 -93.23 -59.45 -22.77
Operating Margin -509.52% -481.29% -808.22% 31.64% -181.62% -104.87% -52.99% -16.15%
Earnings before Tax (EBT) 1 -146 -180.1 -212.4 135.2 -119.2 -81.46 -37.98 -35.51
Net income 1 -145.4 -180.6 -211.8 124.3 -118.7 -65.33 -43.71 -47.1
Net margin -492.27% -463.54% -794.01% 30.14% -156.13% -73.49% -38.96% -33.4%
EPS 2 -3.830 -3.580 -4.110 1.900 -1.720 -1.124 -0.9102 -0.9275
Free Cash Flow 1 -88.18 -155.7 -204.9 - -120.8 -73 -97 -
FCF margin -298.45% -399.77% -767.82% - -158.89% -82.12% -86.47% -
FCF Conversion (EBITDA) - - - - - - - -
FCF Conversion (Net income) - - - - - - - -
Dividend per Share 2 - - - - - - - -
Announcement Date 3/2/20 2/24/21 2/24/22 3/7/23 3/6/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4
Net sales 1 4.395 19.87 1.916 5.442 2.631 402.5 35.58 7.002 16.51 16.93 16.43 32.89 12.83 46.1
EBITDA 1 -59.55 -39.85 -70.22 -64.29 - - - - - -21.21 -28.82 -28.63 -28.44 -
EBIT 1 -60.96 -40.85 -72.69 -65.82 -50.36 319.4 -27.28 -54.11 -33.24 -23.42 -23.81 -33.43 -32.21 6.891
Operating Margin -1,387.12% -205.58% -3,793.63% -1,209.54% -1,914.03% 79.35% -76.68% -772.84% -201.36% -138.37% -144.91% -101.65% -251.06% 14.95%
Earnings before Tax (EBT) 1 -59.82 -40.52 -72.7 -64.63 -47.88 320.4 -22.96 -49.5 -27.58 -19.2 -23 -26.03 -27.94 -4.488
Net income 1 -60.58 -39.15 -72.62 -64.62 -47.85 309.4 -24.35 -51.15 -28.69 -14.48 -23.28 -0.2258 -29.56 -12.03
Net margin -1,378.36% -197.04% -3,790.45% -1,187.41% -1,818.55% 76.88% -68.45% -730.53% -173.8% -85.56% -141.67% -0.69% -230.38% -26.09%
EPS 2 -1.170 -0.7600 -1.190 -0.9700 -0.7200 4.650 -0.3600 -0.7600 -0.4100 -0.2000 -0.3211 0.006110 -0.4047 -0.1611
Dividend per Share 2 - - - - - - - - - - - - - -
Announcement Date 11/3/21 2/24/22 5/4/22 8/4/22 11/8/22 3/7/23 5/8/23 8/10/23 11/7/23 3/6/24 - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - - - - -
Net Cash position 1 299 242 202 - 158 296 355 -
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow 1 -88.2 -156 -205 - -121 -73 -97 -
ROE (net income / shareholders' equity) -68.3% -55.1% -64.3% - -24.8% -19.3% -38.3% -
ROA (Net income/ Total Assets) -47.5% -39.8% -45.7% - -19.3% -13.3% -17.9% -
Assets 1 306.3 453.3 463.8 - 614.8 490.8 244.8 -
Book Value Per Share 6.210 8.140 5.340 - - - - -
Cash Flow per Share -2.150 - - - - - - -
Capex 1 6.32 4.31 12.4 - 2.47 5.5 5.5 1
Capex / Sales 21.4% 11.07% 46.49% - 3.25% 6.19% 4.9% 0.71%
Announcement Date 3/2/20 2/24/21 2/24/22 3/7/23 3/6/24 - - -
1USD in Million
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
8.26 USD
Average target price
14.17 USD
Spread / Average Target
+71.51%
Consensus
  1. Stock Market
  2. Equities
  3. ZYME Stock
  4. Financials Zymeworks Inc.